Merck & Co debuts Nexplanon in USA; gets negative FDA response on Zoely and Saflutan
Merck & Co (NYSE; MRK), the USA’s second largest drugmaker, says that its Nexplanon (etonogestrel implant) 68mg, a long-acting, progestin-only single-rod hormonal implanted contraceptive, is now available in the USA.
The drug is approved by the Food and Drug Administration for the prevention of pregnancy in women for up to three years. Nexplanon must be removed by the end of the third year and may be replaced by a new implant, if continued contraceptive protection is desired.
About the size of a matchstick, Nexplanon is made of a soft, flexible, medical polymer and is inserted just under the skin of a woman's upper arm in a minor surgical in-office procedure. All health care providers performing insertions and/or removals of Nexplanon should receive instructions and training prior to inserting or removing the implant.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze